Immunotherapeutic compositions
AssigneesGlaxosmithkline Biologicals SA, Variation Biotechnologies Inc.
InventorsKirsten SCHNEIDER-OHRUM, David Evander ANDERSON
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM) which comprise virus-like particles (VLPs) comprising murine leukemia virus (MLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with an adjuvant comprising a saponin and a TLR4 agonist.
Claims21
An immunogenic composition comprising:
- (i) a virus like particle (VLP) comprising:
- (a) a murine leukemia virus (MLV) gag protein;
- (b) an HCMV pp65 protein;
- and
- (c) an HCMV glycoprotein B (gB) protein;
- and
- (ii) an adjuvant comprising a saponin and a TLR4 agonist.
A kit for the preparation of an immunogenic composition, said kit comprising:
- (i) a first container comprising a virus like particle comprising:
- (a) a murine leukemia virus (MLV) gag protein;
- (b) an HCMV pp65 protein;
- and
- (c) an HCMV glycoprotein B (gB) protein;
- and
- (ii) a second container comprising an adjuvant comprising a saponin and a TLR4 agonist.
A method for eliciting an immune response in a subject, said method comprising the administration of a saponin, a TLR4 agonist and a virus like particle comprising:
- (a) a murine leukemia virus (MLV) gag protein;
- (b) an HCMV pp65 protein;
- and
- (c) an HCMV glycoprotein B (gB) protein.
A method for the treatment of an HCMV associated cancer in a subject, said method comprising the administration of a saponin, a TLR4 agonist and a virus like particle comprising:
- (a) a murine leukemia virus (MLV) gag protein;
- (b) an HCMV pp65 protein;
- and
- (c) an HCMV glycoprotein B (gB) protein.
Dependencies are inferred from the claim text.